Sugi Predict

Sugi Predict / Compounds / SCHEMBL3738697

SCHEMBL3738697

SCHEMBL3738697

CC(=O)N[C@H]1[C@@H](O[C@H]2O[C@H](CC(O)[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)[C@H](O)[C@H](O)[C@H]2NC(=O)/C=C/CC(C)C)O[C@H](CO)[C@@H](O)[C@@H]1O

nearest known ligand 0.83

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.59
▸ APEX1 P27695 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ MAPT P10636 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ P2RY14 Q15391 5/20 0.52
▸ P2RY2 P41231 2/20 0.52
▸ P2RY6 Q15077 2/20 0.52
▸ P2RY4 P51582 1/20 0.52
▸ OGT O15294 2/20 0.46
▸ SLC28A1 O00337 1/20 0.45
▸ SLC28A2 O43868 1/20 0.45
▸ SLC29A1 Q99808 1/20 0.45
▸ SLC28A3 Q9HAS3 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13210232 1.00 MEN1 (0.59) MEN1APEX1KMT2AMAPTSMN1; SMN2
SCHEMBL30438116 1.00 MEN1 (0.59) MEN1APEX1KMT2AMAPTSMN1; SMN2
SCHEMBL25269457 1.00 MEN1 (0.59) MEN1APEX1KMT2AMAPTSMN1; SMN2
SCHEMBL25251763 1.00 MEN1 (0.59) MEN1APEX1KMT2AMAPTSMN1; SMN2
Tunicamycin SCHEMBL29352796 0.96 MEN1 (0.55) MEN1APEX1KMT2AMAPTSMN1; SMN2
SCHEMBL20412283 0.94 MEN1 (0.52) MEN1APEX1KMT2AMAPTSMN1; SMN2
Tunicamycin B SCHEMBL21597944 0.91 MEN1 (0.72) MEN1APEX1KMT2AMAPTSMN1; SMN2
SCHEMBL21597951 0.91 MEN1 (0.72) MEN1APEX1KMT2AMAPTSMN1; SMN2
Streptovirudin B2A SCHEMBL21597942 0.91 MEN1 (0.72) MEN1APEX1KMT2AMAPTSMN1; SMN2
SCHEMBL21597940 0.91 MEN1 (0.72) MEN1APEX1KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4710932-A1 COMPOSITIONS COMPRISING MANGANESE FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE Administración General de la Comunidad Autónoma de Euskadi (ES) 2026-03-18 — — EP disclosed
US-20250325663-A1 MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER TORAY INDUSTRIES, INC. (JP) 2025-10-23 — — US disclosed
US-20250136662-A1 CD95 POLYPEPTIDES Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2025-05-01 — — US disclosed
EP-4436670-A1 CD95 POLYPEPTIDES Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2024-10-02 — — EP disclosed
CN-118680909-A Application of xanthone in preparing PERK protein phosphorylation inhibitor and preparing neuroprotection and cognition improving drugs 成都中医药大学 2024-09-24 — — CN disclosed
CN-118490899-A Preparation method and application of heparin tunicamycin coating pure magnesium alloy absorbable stent 江苏祥澜医疗科技有限公司 2024-08-16 — — CN disclosed
US-20240197760-A1 ACTIVATORS OF INTEGRATED STRESS RESPONSE PATHWAY FOR PROTECTION AGAINST FERROPTOSIS Burke Neurological Institute 2024-06-20 — — US disclosed
EP-4378477-A1 MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER Toray Industries, Inc. (JP) 2024-06-05 — — EP disclosed
CN-117651566-A Medicine for treating and/or preventing cancer 东丽株式会社 2024-03-05 — — CN disclosed
WO-2023094527-A1 CD95 POLYPEPTIDES Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2023-06-01 — — WO disclosed
EP-2387396-B1 AGENT FOR PREVENTING AND TREATING PITYRIASIS VERSICOLOR JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) 2017-11-15 — — EP disclosed
EP-2846788-A1 USE OF COMPOUNDS FOR THE TREATMENT OF PAIN Akron Molecules AG (AT) 2015-03-18 — — EP disclosed
US-8765712-B2 Agent for preventing and treating pityriasis versicolor JUSTUS-LIEBIG-UNIVERSITAET GIESSEN (DE) 2014-07-01 — — US disclosed
US-8642040-B2 Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists BIOGEN IDEC MA INC. (US) 2014-02-04 — — US disclosed
WO-2013167743-A1 USE OF COMPOUNDS FOR THE TREATMENT OF PAIN AKRON MOLECULES GMBH (AT) 2013-11-14 — — WO disclosed
CN-102119935-B Application of tunicamycin in preparing medicament for treating ischemic cerebral apoplexy UNIV SOOCHOW 2012-09-26 — — CN disclosed
US-20120129800-A1 Agent For Preventing And Treating Pityriasis Versicolor JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) 2012-05-24 — — US disclosed
US-20100074907-A1 Methods for Promoting Myelination, Neuronal Survival and Oligodendrocyte Differentiation Via Administration of SP35 or TrkA Antagonists BIOGEN IDEC MA INC. 2010-03-25 — — US disclosed
EP-2068866-A2 METHODS FOR PROMOTING MYELINATION, NEURONAL SURVIVAL AND OLIGODENDROCYTE DIFFERENTIATION VIA ADMINISTRATION OF SP35 OR TRKA ANTAGONISTS Biogen Idec MA Inc. (US) 2009-06-17 — — EP disclosed
WO-2008013782-A2 METHODS FOR PROMOTING MYELINATION, NEURONAL SURVIVAL AND OLIGODENDROCYTE DIFFERENTIATION VIA ADMINISTRATION OF SP35 OR TRKA ANTAGONISTS BIOGEN IDEC MA INC. (US) 2008-01-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100074907-A1 Methods for Promoting Myelination, Neuronal Survival and Oligodendrocyte Differentiation Via Administration of SP35 or TrkA Antagonists MAG, PMP22, GAP43 MEN1 4470/4885APEX1 4768/4885KMT2A 966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback